Arthur Babakhanians, MD
Family Medicine · Glendale, CANPI 1285183269
Payments from drug & device makers
Across 61 payments — averaging $687.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$40K
- Edwards Lifesciences$330
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$238
- Amgen$214
- Boston Scientific$211
- Galderma Laboratories, L.p.$141
- plus $479 from 13 others
What the payments were for
- Food & beverage$1,9385%
- Gifts$40,00095%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 19 | $40,325 |
| Edwards Lifesciences | 2 | $330 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $238 |
| Amgen | 9 | $214 |
| Boston Scientific | 2 | $211 |
| Galderma Laboratories, L.p. | 6 | $141 |
| Johnson & Johnson | 3 | $80 |
| AstraZeneca | 3 | $67 |
| Ironwood Pharmaceuticals, Inc | 2 | $45 |
| Lilly USA, LLC | 2 | $42 |
| Novo Nordisk | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| Abbott | 1 | $34 |
| Pfizer | 1 | $28 |
| Boehringer Ingelheim | 1 | $26 |
| GSK | 1 | $22 |
| Genentech USA, Inc. | 1 | $22 |
| Merck | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,938 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 100 | $123,244 |
| JardianceEmpagliflozin | 136 | $95,788 |
| OzempicSemaglutide | 65 | $77,945 |
| EliquisApixaban | 103 | $65,804 |
| Metformin Er GastricMetformin Hcl | 43 | $64,985 |
| VascepaIcosapent Ethyl | 173 | $58,224 |
| JanumetSitagliptin Phos/Metformin Hcl | 69 | $44,374 |
| LinzessLinaclotide | 67 | $40,570 |
| JanuviaSitagliptin Phosphate | 44 | $32,158 |
| Diclofenac Sodium | 142 | $29,049 |
| BrilintaTicagrelor | 57 | $27,497 |
| TrulicityDulaglutide | 22 | $25,630 |
| CreonLipase/Protease/Amylase | 32 | $23,950 |
| Lactulose | 27 | $22,145 |
| XareltoRivaroxaban | 45 | $21,663 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $26 | $114,411169 claims |
| Novo NordiskOzempic | $40 | $77,94565 claims |
| MerckJanumet, Januvia | $18 | $76,532113 claims |
| AbbVieLinzess, Creon, Namzaric | $40,325 | $75,638114 claims |
| PfizerEliquis | $28 | $65,804103 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $42 | $39,58435 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $22 | $39,57283 claims |
| AstraZenecaBrilinta, Farxiga | $67 | $35,29371 claims |
| Johnson & JohnsonXarelto | $80 | $21,66345 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Glendale
- Esther YoonGlendale$5.8M
- David HanGlendale$2.3M
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.